Norwegian Cruise Line Holdings Ltd (NCLH) Stock Price Today
Aura AI Summary
Key Stats
- $7.07BMarket Cap
- -Volume
- Consumer CyclicalSector
- $26.9452W High
- $14.7952W Low
- -Typical Hold Time
- $21.88BEnterprise Value
- -Div Yield
- -Trading Activity
Track Norwegian Cruise Line Holdings Ltd (NCLH) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Norwegian Cruise Line Holdings Ltd has traded between a low of $14.79 and a high of $26.94, highlighting its annual price range. Buy and sell Norwegian Cruise Line Holdings Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Most Recent News
Ethereum ETFs see $24M outflow after $824M inflow week, signaling a possible pause, not a trend shift.
Ethereum ETFs experienced a $24.29 million outflow on September 8, 2026, following two weeks of record inflows totaling over $1 billion. Most of the outflow came from Grayscale's funds, which have a history of outflows, while BlackRock's and Fidelity...

Class action lawsuit filed against TruGolf for alleged securities violations and share dilution.
A class action lawsuit has been filed against TruGolf Holdings, Inc. and certain officers for alleged violations of federal securities laws during September 2025 to May 2026. The lawsuit claims TruGolf failed to disclose significant dilution caused b...

Class action lawsuit filed against Replimune for alleged securities law violations over misleading FDA data disclosures.
A class action lawsuit has been filed against Replimune Group, Inc. and some of its officers for allegedly making false statements and failing to disclose critical information about FDA study design concerns and incomplete data submissions during Oct...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.